drugset / Trial / NCT05942300
CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer
Phase 1
Recruiting
30 enrolled
Lan Coffman
National Cancer Institute (NCI) · collabNovartis Pharmaceuticals · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a clinical trial using CPI-0209 in combination with Carboplatin chemotherapy followed by CPI-0209 maintenance in patients with platinum sensitive, recurrent ovarian cancer.
Timeline
- Start
- 2024-01-30
- Primary completion
- 2028-07-31
- Completion
- 2029-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tulmimetostat | Small molecule | 100 mg | Oral |
| Subject | Tulmimetostat | Small molecule | 150 mg | Oral |
| Background | Carboplatin | Small molecule | — | Intravenous |